Compare ESLT & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESLT | RPRX |
|---|---|---|
| Founded | 1966 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8B | 28.4B |
| IPO Year | 2002 | 2020 |
| Metric | ESLT | RPRX |
|---|---|---|
| Price | $722.69 | $68.70 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $841.50 | $73.50 |
| AVG Volume (30 Days) | 69.3K | ★ 3.1M |
| Earning Date | 11-17-2026 | 11-04-2026 |
| Dividend Yield | 0.52% | ★ 1.37% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $14.64 | $49.27 |
| Revenue Next Year | $14.29 | $9.11 |
| P/E Ratio | $71.88 | ★ $66.67 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $453.00 | $37.31 |
| 52 Week High | $1,016.06 | $70.37 |
| Indicator | ESLT | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 65.30 |
| Support Level | $650.34 | $55.48 |
| Resistance Level | $743.83 | N/A |
| Average True Range (ATR) | 24.43 | 1.59 |
| MACD | -4.20 | -0.06 |
| Stochastic Oscillator | 41.59 | 64.56 |
Elbit Systems Ltd is a technology company involved in producing a portfolio of systems and products for aircraft, land, and naval applications. The company's products are used for defense, homeland security and commercial flight capabilities. Its systems and solutions may be installed on new platforms or it may perform a comprehensive modernization program to transform a platform. Elbit Systems gives instructions to its customers on the proper maintenance of its products and will provide support team specialists when the customer cannot fix a problem. The company operates in five segments: Aerospace; C4I and Cyber; ISTAR and EW; Land; and ESA. It derives maximum revenue from Land Segment. Geographically, it operates in Israel; North America; Europe; Asia-Pacific; Latin America; and Others.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.